An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
List view / Grid view
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of…